Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: Estimating the burden of antibiotic resistance in Europe

PLoS Medicine

Volumn 8, Issue 10, 2011, Pages

  de Kraker, Marlieke E A ^a,b   Davey, Peter G ^c   Grundmann, Hajo ^a,b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Quality Safety and Informatics Research Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; METICILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOODSTREAM INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SURVEILLANCE; ESCHERICHIA COLI; EUROPE; HEALTH CARE SYSTEM; HEALTH STATISTICS; HOSPITAL RUNNING COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; PREVALENCE; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; BACTEREMIA; DRUG EFFECT; ECONOMICS; ESCHERICHIA COLI INFECTION; HOSPITAL COST; LENGTH OF STAY; STAPHYLOCOCCUS INFECTION;

BACTEREMIA; CEPHALOSPORIN RESISTANCE; COHORT STUDIES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; EUROPE; HOSPITAL COSTS; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS;

EID: 80055031553     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001104     Document Type: Article

References (40)

1. (2010) BURDEN: Burden of resistance and disease in European nations [website]. Available: http://www.eu-burden.info/. Accessed 1 October 2010.
2. Biedenbach DJ, Moet GJ, Jones RN, (2004) Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 50: 59-69.
3. De Kraker MEA, Wolkewitz M, Davey PG, KollerBerger WJ, (2011) Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 55: 1598-1605.
4. De Kraker MEA, Wolkewitz M, Davey PG, Koller W, Berger J, et al. (2011) Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 66: 398-407.
5. European Antimicrobial Resistance Surveillance Network (2010) Reporting protocol: EARS-Net 2010. European Centre for Disease Prevention and Control. Available: http://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Documents/2010_EARS-Net_Reporting%20Protocol.pdf. Accessed 1 November 2010.
6. European Antimicrobial Resistance Surveillance System (2008) EARSS annual report 2007: on-going surveillance of S. pneumoniae, S aureus, E. coli, E. faecium, E. faecalis, K. pneumoniae, P. aeruginosa. Bilthoven: National Institute for Public Health and the Environment. Available: http://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Documents/2007_EARSS_Annual_Report.pdf. Accessed 1 November 2010.
7. Eurostat (2010) Statistics Database [database]. Available: http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home. Accessed 1 August 2010.
8. Organisation for Economic Co-operation and Development (2010) Health care resources: Hospital beds [database]. Available: http://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT. Accessed 8 September 2011.
9. World Health Organization (2010) Global health observatory [database]. Available: http://apps.who.int/ghodata/. Accessed 1 August 2010.
10. Bender R, Blettner M, (2002) Calculating the "number needed to be exposed" with adjustment for confounding variables in epidemiological studies. J Clin Epidemiol 55: 525-530.
11. Adam T, Evans DB, Murray CJ, (2003) Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 1: 3.
12. World Health Organization (2011) WHO-Choice unit cost estimates for service delivery. Available: http://www.who.int/choice/country/WHO-CHOICEunit_cost_estimates_2007_2008.xls. Accessed 8 September 2011.
13. Eurostat (2010) Harmonized indices of consumer prices: July 2010. Available: http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-QA-10-036/EN/KS-QA-10-036-EN.PDF. Accessed 1 October 2010.
14. Central Bureau of Statistics (2010) Statistical abstract of Israel 2010: consumer price index. Available: http://www1.cbs.gov.il/shnaton61/st13_03.pdf. Accessed 1 October 2010.
15. Croatian Bureau of Statistics (2005) Consumer price indices. Available: http://www.dzs.hr/default_e.htm [search term: consumer price indices]. Accessed 1 October 2010.
16. Turkish Statistical Institute (2010) Consumer Price Index Turkey. Available: http://www.turkstat.gov.tr/PreIstatistikTablo.do?istab_id=652. Accessed 1 October 2010.
17. OANDA Corporation (2011) Historical exchange rates. Available: http://www.oanda.com/currency/historical-rates. Accessed 8 September 2011.
18. McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, et al. (2003) Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 9: 424-430.
19. Mevius DJ, Sprenger MJ, Wegener HC, (1999) EU conference 'The Microbial Threat'. Int J Antimicrob Agents 11: 101-105.
20. European Antimicrobial Resistance Surveillance System (2009) EARSS annual report 2008: on-going surveillance of S. pneumoniae, S aureus, E. coli, E. faecium, E. faecalis, K. pneumoniae, P. aeruginosa. Bilthoven: National Institute for Public Health and the Environment. Available: http://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Documents/2008_EARSS_Annual_Report.pdf. Accessed 1 November 2010.
21. Devaux I, Manissero D, Fernandez de la Hoz K, Kremer K, van Soolingen D, (2010) Surveillance of extensively drug-resistant tuberculosis in Europe, 2003-2007. Euro Surveill 15: 19518.
22. Cosgrove SE, (2006) The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 42 (Suppl 2): S82-S89.
23. Jones RN, (2003) Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 24: 121-134.
24. Boyce JM, White RL, Spruill EY, (1983) Impact of methicillin-resistant Staphylococcus aureus on the incidence of nosocomial staphylococcal infections. J Infect Dis 148: 763.
25. Asgeirsson H, Gudlaugsson O, Kristinsson KG, Heiddal S, Kristjansson M, (2011) Staphylococcus aureus bacteraemia in Iceland, 1995-2008: changing incidence and mortality. Clin Microbiol Infect 17: 513-518.
26. Wyllie DH, Crook DW, Peto TE, (2006) Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 333: 281.
27. Wilson J, Elgohari S, Livermore DM, Cookson B, Johnson A, et al. (2011) Trends among pathogens reported as causing bacteraemia in England, 2004-2008. Clin Microbiol Infect 17: 451-458.
28. Marchaim D, Zaidenstein R, Lazarovitch T, Karpuch Y, Ziv T, et al. (2008) Epidemiology of bacteremia episodes in a single center: increase in Gram-negative isolates, antibiotics resistance, and patient age. Eur J Clin Microbiol Infect Dis 27: 1045-1051.
29. Sax H, Pittet D, (2002) Interhospital differences in nosocomial infection rates: importance of case-mix adjustment. Arch Intern Med 162: 2437-2442.
30. Tong EN, Clements AC, Haynes MA, Jones MA, Morton AP, et al. (2009) Improved hospital-level risk adjustment for surveillance of healthcare-associated bloodstream infections: a retrospective cohort study. BMC Infect Dis 9: 145.
31. Jarlier V, Arnaud I, Carbonne A, (2009) Surveillance des bactéries multirésistantes dans les établissements de santé en France. Réseau BMR-Raisin. Résultats 2007. Available: http://www.invs.sante.fr/publications/2009/bmr_raisin_2007/BMR_Raisin_resultats_2007.pdf. Accessed 1 November 2010.
32. Benfield T, Espersen F, Frimodt-Moller N, Jensen AG, Larsen AR, et al. (2007) Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect 13: 257-263.
33. Antibiotika Resistenz Surveillance (2010) Resistenzübersicht [database]. Robert Koch-Institut. Available: https://ars.rki.de/CommonReports/Resistenzuebersicht.aspx. Accessed 3 April 2011.
34. Wolkewitz M, Frank U, Philips G, Schumacher M, Davey P, (2011) Mortality associated with in-hospital bacteraemia caused by Staphylococcus aureus: a multistate analysis with follow-up beyond hospital discharge. J Antimicrob Chemother 66: 381-386.
35. Lambert ML, Suetens C, Savey A, Palomar M, Hiesmayr M, et al. (2011) Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 11: 30-38.
36. European Centre for Disease Control, European Medicines Agency (2009) The bacterial challenge: time to react. A call to narrow the gap between multi-drug resistant bacteria in the EU and the development of new antibacterial agents. Available: http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf. Accessed 1 November 2010.
37. World Health Organization (2004) The global burden of disease: 2004 update. Available: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. Accessed 1 November 2010.
38. Struelens MJ, Monnet DL, (2010) Prevention of methicillin-resistant Staphylococcus aureus infection: is Europe winning the fight? Infect Control Hosp Epidemiol 31 (Suppl 1): S42-S44.
39. Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, et al. (2010) Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Eurosurveillance 15: 19711.
40. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, et al. (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10: 597-602.